Weight Loss Medication Users Exhibit Decreased Physical Activity, Warns Recent Study
A groundbreaking study unveiled on June 14, 2026, at the annual ENDO 2026 meeting of the Endocrine Society in Chicago, reveals a surprising trend among users of popular GLP-1 weight-loss medications. Despite successful weight loss, individuals taking Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide), and Zepbound are exhibiting a significant decrease in physical activity post-treatment initiation.
Researchers from HSHS Saint John’s Hospital in Illinois scrutinized Fitbit wearable data of obesity patients and discovered a decline in daily step counts and moderate-to-vigorous exercise levels following the commencement of GLP-1 therapy. The most substantial declines were noted in males and individuals suffering from musculoskeletal pain.
Contrary to popular belief, weight loss doesn’t necessarily facilitate movement. Experts warn that GLP-1 drugs might also diminish lean muscle mass along with body fat, thereby making regular physical activity even more crucial. Side effects such as fatigue could also contribute to decreased activity. Researchers are urging medical professionals to emphasize to patients initiating these medications the importance of maintaining regular exercise routines. Ideally, this should involve 30 minutes of exercise a day, five days a week, combining both aerobic and resistance training to safeguard muscle health and promote long-term wellness.
Source: ScienceDaily – June 14, 2026